Branch Out Neurological Foundation’s Post

Speech and language impairments are core features of the neurodevelopmental genetic condition Kleefstra syndrome. The speech, language and cognitive profile of Kleefstra syndrome is broad, ranging from severe impairment to average ability. Genotype and age do not explain the phenotypic variability. Early access to communication aids may improve communication and quality of life. In this study, Redenlab partnered with team building evidence for measuring and describing communication in rare paediatric diseases. This study was conducted by Lottie Morison, Milou Kennis, Dmitrijs Rots, Arianne Bouman, Joost Kummeling, Elizabeth Emma Palmer, Adam Vogel, Frederique Liegeois, Amanda Brignell, Siddharth Srivastava, Zoë Frazier, Di Milnes, Himanshu Goel, David Amor, Ingrid E. Scheffer, Tjitske Kleefstra and Angela T. Morgan. They are affiliated with the following organisations: Murdoch Children's Research Institute (MCRI), University of Melbourne, Radboudumc, Erasmus MC, Sydney Children's Hospitals Network, Randwick, UNSW, UCL, Monash University, Monash Children’s Hospital, Boston Children's Hospital, Genetic Health Queensland, Hunter Genetics, The Royal Children's Hospital, Melbourne Brain Centre, Austin Health and The Florey. To find out more about the study, click here: https://lnkd.in/g4aKrg6i To learn more about Redenlab and our work, click here: https://redenlab.com/ #speech #kleefstrasyndrome #language #communication #cognition #research

A new study by @Lisa Quadt Jessica Eccles and team Brighton and Sussex Medical School studying how might inflammation may impact on children and young people with extreme fatigue and inflammation in the link. We know from previous papers published last year that pain impacts on educational attendance and attainment for children and young people. We are delighted this follows up on this area for neurodivergent individuals in all arenas. Read the paper here : https://lnkd.in/dj5HzDuA #Inflammation #CYP #fatigue #neurodivergence #neurodivergent

Psychedelics have changed people's attitudes toward death. In a study of more than 3,000 adults, the participants reported having less fear of death and dying after their experience. The results are consistent with several recent clinical trials showing that a single treatment with the psychedelic psilocybin produced sustained decreases in anxiety and depression among patients with a life-threatening cancer diagnosis. The largest of these trials (by Roland R. Griffiths) was conducted at Johns Hopkins Medicine. Researchers say that future studies are needed to better understand the potential clinical use of psychedelics in ameliorating suffering related to fear of death. In autumn 2023, David B. Yaden became the inaugural recipient of the Roland R. Griffiths, Ph.D. Professorship Fund in Psychedelic Research on Secular Spirituality and Well-Being. The $24 million endowed professorship, the largest ever at the Johns Hopkins University School of Medicine, aims to advance research on psychedelic substances and their effects on human health, behavior and worldview. You can follow his journey via The Griffiths Fund: https://buff.ly/3OsDOhe As well as David B. Yaden's account on Twitter/X: @ExistWell #hopkinsmedicine #hopkinspsych #psychopharmacology #painrelief #painmanagement #fearofdeath #rolandgriffiths #psychedelics #researcher #death #psychedelic #psychedelicresearch #jhu #johnshopkins #deathanddying #johnshopkinscenter #consciousness #psilocybin

Psychedelics have changed people's attitudes toward death. In a study of more than 3,000 adults, the participants reported having less fear of death and dying after their experience. The results are consistent with several recent clinical trials showing that a single treatment with the psychedelic psilocybin produced sustained decreases in anxiety and depression among patients with a life-threatening cancer diagnosis. The largest of these trials (by Roland R. Griffiths) was conducted at Johns Hopkins Medicine. Researchers say that future studies are needed to better understand the potential clinical use of psychedelics in ameliorating suffering related to fear of death. In autumn 2023, David B. Yaden became the inaugural recipient of the Roland R. Griffiths, Ph.D. Professorship Fund in Psychedelic Research on Secular Spirituality and Well-Being. The $24 million endowed professorship, the largest ever at the Johns Hopkins University School of Medicine, aims to advance research on psychedelic substances and their effects on human health, behavior and worldview. You can follow his journey via The Griffiths Fund: https://buff.ly/3OsDOhe As well as David B. Yaden's account on Twitter/X: @ExistWell #hopkinsmedicine #hopkinspsych #psychopharmacology #painrelief #painmanagement #fearofdeath #rolandgriffiths #psychedelics #researcher #death #psychedelic #psychedelicresearch #jhu #johnshopkins #deathanddying #johnshopkinscenter #consciousness #psilocybin

A Documenting Hope Conference Featured Speaker: Dr. Shelese Pratt ND @drsheleseprattnd She will speak on both the Parent Track and the Health Professional CME track on The Metabolic Approach to Autism Spectrum Disorders Autism is a behaviorally diagnosed disorder with unclear underlying etiology in which effective treatments are lacking. Neuroimaging, neurophysiology, genetic, molecular, and metabolic studies have provided evidence for some of the basic pathophysiological mechanisms underlying autism. Other studies focusing on medical co-morbidities have highlighted the many organ systems associated with autism suggesting that autism manifests as a multisystem disease in some patients. This evidence has started to provide an emerging picture of how biology drives behavior and has pointed to novel promising approaches to treatment. Hear Dr. Pratt speak November 15-17, 2024 at The Omni Orlando at ChampionsGate, Orlando, FL ⁠ 🐦 Lock in the EARLY BIRD RATE & PERKS before May 31st. 🎟️ LEARN MORE RSVP/TICKET PURCHASE:⁠ https://lnkd.in/dyiRmkdJ⁠

💣 Millions wasted, patients at risk and hopes for a cure dashed: Eliezer Masliah’s Misconduct Exposed! 👨🔬 Who is Dr. Eliezer Masliah? - He is one of the most famous Parkinson's and Alzheimer's researchers in the world. - Applications for approval of several drugs are based on his studies, including prasinezumab developed by Prothena Biosciences for the treatment of Parkinson’s - As NIH Director of the National Institute on Aging (NIA), he recently had an annual budget of 2.6 billion US dollars. 🛑 Now, the The National Institutes of Health has confirmed findings of research misconduct, specifically regarding the manipulation and duplication of figures in over 130 scientific publications from 1997 to today! 👉 We must reinforce ethical standards and ensure that our commitment to integrity remains unwavering to prevent such breaches from tarnishing the hard work of countless dedicated researchers. #Accountability #Neuroscience #EthicsInScience https://lnkd.in/e2i4CPpP

💬 "It's important that we work together to address the very high unmet needs of brain disorders". During the 2023 Brain Innovation Days, we asked Prof. Martien Kas, President of the European College of Neuropsychopharmacology (ECNP), his views on the future of innovation in the brain space. 📺 Watch the full interview on YouTube: https://lnkd.in/eaQ9jtr6 🎟 Join the 2024 edition: https://lnkd.in/dtBrYjy2

Yet another study to provide evidence of why prevention and early intervention are the common-sense places to invest our funds. Let's help our children heal now, so they aren't suffering in the areas of physical and behavioral health as adults. #IECMH #earlychildhoodmentalhealth #infantmentalhealth #childparentpsychotherapy #healing #trauma #parenting #mentalhealth #NationalRecoveryMonth #prevention #earlyintervention #attachment #childwelfare

In case you missed it: Recent research builds the case that the #pain system differs between males and females, at the level of pain-sensing neurons. Read more on MSC and learn about the implications of the research for #migraine

In clinical trials developing treatments for #Alzheimers Disease and other #neurodegenerative conditions, changes in cognitive performance may be due to factors besides the treatment itself, such as practice effects or increased comfort with cognitive testing. Through collaborative work with scientists at University of Oxford and University of Cambridge, we have shown that inclusion of a familiarization session - a testing session administered prior to baseline assessment in a longitudinal clinical trial - is useful in limiting the influence of such outside factors. As a means of detecting true treatment effects, we recommend inclusion of a familiarization session for several popular CANTAB tasks, including PAL, RVP and SWM. Read more here: https://lnkd.in/dzTQ6yaH John Bernstein, Ph.D. #CNS #neurodegenerative #familiarisation #cognitiveperformance